KTTA: Pasithea Therapeutics P/S multiplikatori
Pasithea Therapeutics (KTTA) kompaniyasining ventura salohiyati GURU.Markets servisining kunlik grafigi bilan tasdiqlanganidek, kichik molekula patentlariga asoslangan. Sotuvlarga nisbatan narx koeffitsiyenti, bunda 39.40 qiymati joriy raqamni ko'rsatadi, neyrobiologiya segmentidagi sezilarli narx belgilash imkoniyati bilan bog'liq. FDA ning qat'iy tartibga soluvchi qoidalari va klinik sinovlarning yuqori xarajatlari biznes himoyasi vazifasini o'tab, yangi ishtirokchilar uchun kirishning jiddiy to'sig'ini yaratadi.
Pasithea Therapeutics (KTTA) kompaniyasining tahliliy kesimlari
- joriy kotirovkalar va o'rtacha qiymat prognozi:
- bozor kapitallashuvi haqida ma'lumot:
- balans bo'yicha xususiy kapital ma'lumotlari:
- biznesning qarz tarkibi va likvidligi tafsilotlari:
Barcha qarzlarning o‘z mablag‘lariga nisbati Pasithea Therapeutics|KTTA - Uzoq muddatli qarzning kapitalga nisbati|Qisqa muddatli majburiyatlarning kapitalga nisbati pasitheaclinics.com|KTTA - Kompaniya qarzlari|Qarzning sof aktivlarga nisbati Pasithea|KTTA - Kompaniyaning uzoq muddatli qarzlari|Kompaniyaning qisqa muddatli qarzlari Pasithea Therapeutics|Kritik likvidlik koeffitsiyenti pasitheaclinics.com
- foyda va qiymat multiplikatorlari haqida ma'lumot:
KTTA - Sof foyda|Kutilayotgan sof foyda Pasithea Therapeutics|KTTA - Narx-foyda koeffitsiyenti|Forvard P/E multiplikatori pasitheaclinics.com|KTTA - Narx-foyda va o‘sish multiplikatori|Korxona qiymatining amortizatsiyadan oldingi operatsion foydaga nisbati koeffitsiyenti Pasithea|KTTA - EBITDA operatsion foydasi|So'nggi to'rtta chorak uchun bir aksiya uchun sof foyda Pasithea Therapeutics|KTTA - Bir aksiya uchun sof foyda (EPS TTM)|So'nggi 12 oy davomida bir aksiya uchun sof foydaning yillik o'sishi pasitheaclinics.com|KTTA - Joriy yilda bir aksiya uchun foyda o'sishi|Keyingi yil uchun bir aksiya uchun foyda o'sishining konsensus prognozi Pasithea Therapeutics
- sotishdan tushum va biznes daromadlari ko'rsatkichlari:
Kompaniyaning fundamental tahlili:Pasithea Therapeutics Corp, KTTA
Pasithea Therapeutics (KTTA) kompaniyasida sintez va sinov jarayonlarining maksimal darajada autsorsing qilinishi operatsion risklarni tashqi pudratchilarga o'tkazish orqali kapital xarajatlarini minimallashtiradi. Fundamental P/S ko'rsatkichi bilan ifodalangan bozor kapitalizatsiyasining daromadga nisbati investorlarga narxlar tebranishini statik savdo ko'rsatkichlaridan ajratish imkonini beradi va bu esa ixcham boshqaruv tuzilmasiga ega biznes modeli uchun to'lanadigan premiumni aniqlaydi.
Raqobatdosh kompaniyalar
BIIB - Sotuvga nisbatan narx|P/S multiplikatori NBIX (Neurocrine Biosciences, Inc.)|P/S multiplikatori Regencell Bioscience Ltd RGC|AXSM: Kapitalizatsiyaning daromadga nisbati|Bozor kapitallashuvining daromadga nisbati ACAD (ACADIA Corp)|XENE (Xenon Pharmaceuticals) - Kapitalizatsiyaning daromadga nisbati|VKTX: Kapitalizatsiyaning sotish hajmiga nisbati|SUPN (Supernus) - P/S multiplikatori|CPRX: Bozor kapitallashuvining daromadga nisbati|P/S multiplikatori DNLI|HRMY - Sotuvga nisbatan narx|Narxning daromadga nisbati Biohaven Ltd. BHVN|Bozor kapitallashuvining daromadga nisbati AMLX|Trevi Therapeutics, Inc. - P/S multiplikatori|PRAX - P/S multiplikatori|Anavex Corp (AVXL) - Narxning daromadga nisbati|Narxning sotuvga nisbati CBLL (CeriBell EEG)|PRTA (Prothena Biosciences) - P/S multiplikatori|Sotuvga nisbatan narx Alector Therapeutics ALEC|Kapitalizatsiyaning daromadga nisbati ANNX (Annexon)|P/S multiplikatori omeros.com (OMER)|Neurogene Corp - Kapitalizatsiyaning daromadga nisbati|Kapitalizatsiyaning sotish hajmiga nisbati ACIU (AC Immune Inc)|Voyager Therapeutics - P/S multiplikatori|Narx/daromad koeffitsiyenti neumoratx.com NMRA|SCLX: P/S multiplikatori|Kapitalizatsiyaning daromadga nisbati Tevogen Bio Holdings Inc.|Narxning daromadga nisbati Alpha Cognition Inc|Cognition Therapeutics Inc. (CGTX) - Narx/daromad koeffitsiyenti|Narxning daromadga nisbati Inhibikase Therapeutics (IKT)|P/S multiplikatori cassavasciences.com (SAVA)|Assertio - Kapitalizatsiyaning daromadga nisbati|Kapitalizatsiyaning sotish hajmiga nisbati COYA (Coya Therapeutics Inc)|VTGN: Kapitalizatsiyaning daromadga nisbati|Ovid Therapeutics Inc. - Kapitalizatsiyaning sotish hajmiga nisbati|ABOS: P/S multiplikatori|cervomed.com (CRVO) - P/S multiplikatori|Narxning daromadga nisbati Alterity Therapeutics Ltd.|Kapitalizatsiya va daromad nisbati CLNN (Clene Nanomedicine)|P/S multiplikatori PEPG|JUNS - Sotuvga nisbatan narx|Relmada Therapeutics - Kapitalizatsiyaning daromadga nisbati|P/S multiplikatori annovisbio.com ANVS|GRCE - Narxning daromadga nisbati|Bozor kapitallashuvining daromadga nisbati AIFF (Firefly Neuroscience, Inc.)|anewmeds.com (KLTO) - Narxning daromadga nisbati|Sotuvga nisbatan narx NeuroSense Therapeutics Ltd. (NRSN)|Narxning daromadga nisbati Reviva Pharmaceuticals|MetaVia, Inc. - Narxning sotuvga nisbati|P/S multiplikatori NRXS|P/S multiplikatori heliusmedical.com (HSDT)|Narxning daromadga nisbati Passage Bio PASG|Narx/daromad koeffitsiyenti Neuphoria Therapeutics, Inc. (NEUP)|Minerva Neurosciences - P/S multiplikatori|Narx/daromad koeffitsiyenti athira.com ATHA|ADXN (Addex Therapeutics Ltd) - Kapitalizatsiyaning daromadga nisbati|ALZN: Kapitalizatsiyaning sotish hajmiga nisbati|CYCN (Cyclerion Therapeutics Inc.) - P/S multiplikatori|PTIX: Bozor kapitallashuvining daromadga nisbati|P/S multiplikatori CRGT|ATXI - Sotuvga nisbatan narx|P/S multiplikatori BCLI (BrainStorm Cell Therapeutics)|P/S multiplikatori Cara Therapeutics Inc. CARA|CHRO: Kapitalizatsiyaning daromadga nisbati|Bozor kapitallashuvining daromadga nisbati ELYM (Eliem Therapeutics)|ITCI (intracellulartherapies.com) - Kapitalizatsiyaning daromadga nisbati|LBPH: Kapitalizatsiyaning sotish hajmiga nisbati|MRNS (Marinus Pharmaceuticals, Inc.) - P/S multiplikatori|NKGN: Bozor kapitallashuvining daromadga nisbati|P/S multiplikatori NRBO|SAGE - Sotuvga nisbatan narx|Narxning daromadga nisbati Synaptogenix, Inc. SNPX|Bozor kapitallashuvining daromadga nisbati TRVN|Vigil Neuro - P/S multiplikatori|WENA - P/S multiplikatori|Cerevel (CERE) - Narxning daromadga nisbati
